Livagen: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 8 sources cited
Overview
Livagen is a synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Professor Khavinson's research group in Russia, designed to normalize liver function and hepatocyte gene expression. It belongs to the Khavinson bioregulator class of peptides that act on chromatin structure to restore youthful gene expression patterns in specific organ systems.
Mechanism of Action
In cultured lymphocytes from elderly people, Livagen caused decondensation of heterochromatin and release of repressed genes; the same action in hepatocyte nuclei is assumed, not shown. This epigenetic mechanism is proposed to allow aged or damaged liver cells to resume production of proteins essential for detoxification, protein synthesis, and bile metabolism. Livagen activated ribosomal genes in lymphocytes from old people and raised protein synthesis in cultured rat hepatocytes, most strongly in cells from old animals. Effects on cytochrome P450 enzymes or glutathione-S-transferase have not been reported in published studies. Unlike pharmacological liver protectants, Livagen is proposed to work at the gene expression level to restore the liver's intrinsic functional capacity.
Livagen Benefits: What the Research Shows
- Khavinson et al. demonstrated Livagen causes chromatin decondensation in lymphocytes from old people, releasing repressed genes (Bulletin of Experimental Biology and Medicine, 2002)
- A 2020 review by the developers reports that Livagen restored liver function in animal models of hepatitis and liver fibrosis; no study in patients with chronic hepatitis was found
- Research showed Livagen increased protein synthesis in cultured rat hepatocytes, with the largest effect in cells from old rats (Izvestiia Akademii nauk. Seriia biologicheskaia, 2001)
- The developers' review reports that Livagen normalized immune and antioxidant status in animal models of liver disease; no study of detoxification capacity was found
- Long-term studies (6 to 15 years) of the Khavinson group's pineal and thymus extracts (Epithalamin, Thymalin) in elderly patients reported better health indices and lower mortality; they did not include Livagen
Livagen Dosage
- Standard oral protocol: 10–20 mg daily for 10–30 days
- Common protocol: 10 mg oral, 2–3 times daily for 10–15 days, repeated every 3–6 months
- Sublingual: 5–10 mg dissolved under tongue twice daily for improved absorption
- Injectable (less common): 1–5 mg subcutaneous daily for 10 days
- Maintenance: 10 mg daily for 10 days every 3–6 months
- Often used as part of a bioregulator rotation protocol alongside other organ-specific peptides
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Livagen Side Effects & Safety
Known Side Effects
- Tolerability has not been studied in humans; the effects listed below are user reports
- Occasional mild GI discomfort (nausea, bloating) with oral dosing
- Rare: mild headache during first 2–3 days
- Injection site irritation if using injectable form
- Published research is limited to cell and animal studies and contains no human safety data
Safety Profile
Livagen has been studied as part of the Khavinson bioregulator program for over two decades. Its safety is assumed from its small size and natural amino acid composition rather than shown: no toxicology, dose-ranging or human safety study of Livagen is indexed in PubMed. Contraindications: known hypersensitivity. Use with caution in individuals with autoimmune liver conditions. Long-term safety and drug interactions have not been studied. An effect on hepatic drug-metabolizing enzymes is unproven, but caution with narrow-therapeutic-index medications is reasonable.
What to Expect
Days 1–5: No dramatic subjective changes. Gene expression effects have been shown in cell cultures; they have not been measured in people. Some users report subtle improvement in digestive comfort. Days 5–10: Improved sense of well-being. Changes in liver enzymes on blood work, or in tolerance of dietary fats or alcohol, have not been measured in any human study of Livagen. Weeks 2–4 post-course: Full benefits manifest. Users report improved energy. Improvements in liver enzyme panels or detoxification capacity, and how long any effect lasts, have not been documented in human studies. Subsequent courses (every 3–6 months) reinforce and build upon previous improvements.
Common Stacks
Glutathione
Livagen restores hepatocyte detoxification gene expression while glutathione provides the primary substrate for Phase II conjugation — complementary liver support
Epitalon
Epitalon provides systemic anti-aging through telomere protection while Livagen targets liver-specific age-related gene silencing
NAD+
NAD+ supports hepatocyte energy metabolism and sirtuin activation, complementing Livagen's gene expression normalization in liver tissue
Storage & Handling
Store oral capsules at room temperature in a cool, dry place. Injectable form: store lyophilized at 2–8°C; reconstituted at 2–8°C, use within 2–3 weeks. Tetrapeptide bioregulators are relatively stable compounds.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Khavinson VKh, Lezhava TA, Monaselidze JG, et al. Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bull Exp Biol Med. 2002.
- Brodskiĭ VIa, Khavinson VKh, Zolotarev IuA, et al. Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen. Izv Akad Nauk Ser Biol. 2001.
- Kuznik BI, Khasanova NB, Ryzhak GA, et al. The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology. Adv Gerontol. 2020.
- Riadnova IIu, Filippov SV, Iuzhakov VV. Functional morphology of an organotypic liver culture exposed to the peptide livagen. Adv Gerontol. 2002.
- Lezhava T, Jokhadze T. Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. Ann N Y Acad Sci. 2007.
- Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004.
- Timofeeva NM, Khavinson VKh, Malinin VV, et al. Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages. Adv Gerontol. 2005.
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003.
Related Peptides
Track Livagen in Your Protocol
Log your Livagen doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free